Actinium Pharmaceuticals (Delaware) (ATNM) News
NYSE: ATNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.05-0.02 (-1.87%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ATNM news summary
We found 4 recent headlines mentioning Actinium Pharmaceuticals (Delaware) (ATNM): 0 in the past week and 1 in the past 30 days, most often from PR Newswire, Nasdaq. For price context, ATNM is down 1.87% at $1.05. The most recent story, "Actinium Pharmaceuticals Announces Inducement Grant to New Employee", was published by PR Newswire on Oct 30, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Actinium Pharmaceuticals (Delaware) headlines
- Actinium Pharmaceuticals Announces Inducement Grant to New EmployeeNEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an…PR Newswire
- Actinium Pharmaceuticals Announces Inducement Grants to New EmployeesNEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…PR Newswire
- Actinium Pharmaceuticals Names Matt David CFO(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM), a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer, said Thursday it has appointed Matt David as chief…Nasdaq
- Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerNEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…PR Newswire